ClinicalTrials.gg
Active, not recruitingNCT07008378Updated Oct 13, 2026

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

A Phase 1 interventional study of P-CD19CD20-ALLO1 Cells and Cyclophosphamide in Multiple Sclerosis, sponsored by Genentech, Inc.. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Updated Oct 13, 20261 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Multiple Sclerosis by Hoffmann-La Roche — 6 open to participants now, 17 under way, 7 of them phase 3. Multiple Sclerosis · Hoffmann-La Roche.

Planned enrollment
25th of 31
60 · median 134
Started
2025
with 2 others
Phase 1
6 of 35
1 open now
Primary completion
2032-08
later than 16 of 16 live
Registered
29th of 35
by date

Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one is the 25th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 in phase 1, reaches primary completion later than 16 of the 16 other live ones, and was the 29th registered.

Multiple Sclerosis

3,272 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

6 of the 35 studies in Multiple Sclerosis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Multiple Sclerosis by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-60 years (inclusive) at the time of signing Form
  • Diagnosis of progressive MS according to the revised McDonald 2017 criteria, and:

Expanded disability status scale (EDSS) score at screening, from 3 to 6 inclusive Evidence of disability progression and no relapses in the 2 years prior to screening

- Diagnosis of relapsing MS according to the revised McDonald 2017 criteria, and: Evidence of clinical relapses and MRI activity within two years prior to screening while on a disease modifying therapy

  • EDSS score at screening, from 0 to 6 inclusive
  • No relapses within 45 days of screening

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intention of becoming pregnant within the timeframe in which is required
  • Participants who have confirmed or suspected Progressive Multifocal Leukoencephalopathy (PML)
  • Known or suspected history of Hemophagocytic Lymphohistiocytosis/ Macrophage Activation Syndrome (HLH/MAS) or neurotoxicity with prior therapies
  • Known presence of other neurologic disorders that may mimic MS
  • History of currently active primary or secondary (non-drug-related) immunodeficiency
  • Significant or uncontrolled medical disease which would preclude patient participation
  • High risk for bleeding or any condition requiring plasmapheresis, IV Ig, or acute blood product transfusions
  • History of recurrent serious infections or chronic infection
  • Prior treatment with CAR T-cell therapy, gene-therapy product, total body irradiation, bone marrow transplantation, allograft organ transplant, or hematopoietic stem cell transplant at any point
  • Any previous treatment with immunomodulatory or medication without an appropriate .
  • Inability to complete an MRI scan
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Participants will receive a lymphodepleting chemotherapy regimen followed by a single infusion of P-CD19CD20-ALLO1. Dose escalation decisions will be made after participants are observed for a minimum of 28 days for toxicity.

    Biological: P-CD19CD20-ALLO1 Cells · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

  • BiologicalP-CD19CD20-ALLO1 Cells

    P-CD19CD20-ALLO1 Cells will be administered intravenously as per the schedule specified in the protocol.

  • Cyclophosphamide will be administered intravenously.

  • Fludarabine will be administered intravenously.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicity (DLTs) at Each Dose Level of P-CD19CD20-ALLO1

    Time frame: Day 1 up to Day 29

  2. Number of Participants With Adverse Events (AEs)

    Time frame: Up to 5 years

Secondary outcomes

  1. Number of Chimeric Antigen Receptor (CAR) Transgene Copies in Blood Assessed by Droplet Digital Polymerase Chain Reaction (ddPCR)

    Time frame: Up to 5 years

  2. B-cell Levels in the Blood

    Time frame: Up to 5 years

  3. Number of Participants With Anti-CAR T Antibodies

    Time frame: Up to 5 years

07

Study locations

4 sites
  • UCSD Altman Clinical and Translational Research Institute
    La Jolla, California 92037-1337, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110-1010, United States
  • Rutgers University- Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901-1962, United States
  • Multiple Sclerosis Comprehensive Care Center at Northwell Health
    New York, New York 10075, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2032, 82 months after the start.

Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 82 months is above that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
Jun 6, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Aug 31, 2032
CompletionEst.
Aug 31, 2032
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • UCI Sue & Bill Gross Stem Cell Research Center · Irvine, United States
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site removed
    Show 1 removed
    • UCI Sue & Bill Gross Stem Cell Research Center · Irvine, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07008378
Lead sponsor
Genentech, Inc.
Collaborators
Poseida Therapeutics, Inc., a member of the Roche Group
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Oct 15, 2025
Primary completion
Aug 31, 2032 (estimated)
Completion
Aug 31, 2032 (estimated)
Last update
Oct 13, 2026

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion